Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure
This study has been completed.
Sponsor:
Covidien
Information provided by (Responsible Party):
Covidien
ClinicalTrials.gov Identifier:
NCT01169311
First received: July 22, 2010
Last updated: June 18, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Trial Objectives
The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set:
overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.
Condition | Intervention | Phase |
---|---|---|
Hemorrhoid |
Device: THE COVIDIEN EEA™ HEMORRHOID AND PROLAPSE STAPLING SET |
Phase 4 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Prospective, Multi-Center Investigation Of The Safety And Performance Of The Covidien EEA™ Hemorrhoid And Prolapse Stapling Set With DST Series™ Technology Im A Hemorrhoidopexy Procedure |
Resource links provided by NLM:
Further study details as provided by Covidien:
Primary Outcome Measures:
- Safety and Efficacy [ Time Frame: 30 days ] [ Designated as safety issue: No ]
The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set:
overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.
Enrollment: | 30 |
Study Start Date: | July 2010 |
Study Completion Date: | July 2011 |
Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Device: THE COVIDIEN EEA™ HEMORRHOID AND PROLAPSE STAPLING SET
The Covidien EEA™ Hemorrhoid and Prolapse Stapler Set with DST Series™ Technology is designed for use as a stapler instrument for control of rectal prolapse and hemorrhoid disease.
Other Name: THE COVIDIEN EEA™ HEMORRHOID AND PROLAPSE STAPLING SET
Eligibility
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Able to understand and sign Informed Consent Form
- The participant must be 18-80 years of age.
- The participant has (symptomatic) Grade 2-4 Hemorrhoids and is eligible for stapled hemorrhoidopexy.
Exclusion Criteria:
- The procedure is needed as revision hemorrhoid surgery.
- The participant is pregnant.
- The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.
- The participant is unable or unwilling to comply with the study requirements, follow-up schedule.
- The participant has a history of drug or alcohol abuse.
- The participant has a history of venous thrombosis or pulmonary embolism.
- The participant has a history of coagulopathy.
- The participant is taking aspirin, anti-coagulation and/or anti platelet therapies (e.g.: Warfarin, Levonox) within the last 7 days prior to the planned surgery date
- The participant has a history of fecal incontinence.
- The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01169311
Locations
United States, New York | |
Weill Cornell Medical Center | |
New York, New York, United States, 10065 |
Sponsors and Collaborators
Covidien
Investigators
Principal Investigator: | Sang Lee, M.D. | Weill Medical College of Cornell University |
More Information
No publications provided
Keywords provided by Covidien:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Covidien |
ClinicalTrials.gov Identifier: | NCT01169311 History of Changes |
Other Study ID Numbers: | COVHEPH0021 |
Study First Received: | July 22, 2010 |
Last Updated: | June 18, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Covidien:
Hemorrhoids Hemorrhoid grade II, III, IV |
Additional relevant MeSH terms:
Hemorrhoids Prolapse Rectal Diseases Intestinal Diseases Gastrointestinal Diseases |
Digestive System Diseases Vascular Diseases Cardiovascular Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on October 17, 2012